Skip to main content
Top
Published in: Annals of Surgical Oncology 7/2018

01-07-2018 | Pancreatic Tumors

A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer

Authors: Takehiro Okabayashi, MD, Yasuo Shima, MD, Tatsuaki Sumiyoshi, MD, Kenta Sui, MD, Jun Iwata, MD, Sojiro Morita, MD, Yasuhiro Shimada, MD, Tatsuo Iiyama, MD

Published in: Annals of Surgical Oncology | Issue 7/2018

Login to get access

Abstract

Background

Preoperative methods to estimate disease-specific survival (DSS) for resectable pancreatic cancer are limited.

Objective

The aim of this study was to develop and validate a pretreatment physiobiological prognostic model in patients with radiologically resectable pancreatic cancer.

Methods

A retrospective review of a prospectively maintained institutional database was undertaken to identify patients who underwent potentially curative resection for radiologically resectable pancreatic cancer. Demographics, treatments, and relationships between the potential prognostic factors and survival rate were analyzed, and prognostic nomograms were established.

Results

We identified 240 patients who fulfilled our eligible criteria. The 1-, 3-, and 5-year DSS rates after surgery were 77.8, 40.9, and 31.3%, respectively. On multivariate analysis, increased neutrophil/lymphocyte ratio [hazard ratio (HR) 1.60, 95% confidence interval (CI) 1.17–2.17; p < 0.01], reduced Prognostic Nutritional Index (HR 2.08, 95% CI 1.68–3.20; p < 0.01), and elevated preoperative serum carbohydrate antigen 19-9 level (HR 2.12, 95% CI 1.55–2.88; p < 0.01) were associated with worse DSS. Although curative resection was the operative aim for all patients, 131 (54.6%) patients had recurrence within 12 months after curative resection of resectable pancreatic cancer. There was a significant correlation between recurrence pattern and physiobiological characteristics.

Conclusion

We developed a new grading system for radiologically resectable pancreatic cancer. This system is simple and reliably predicts differences in survival after pancreatic resection.
Literature
2.
go back to reference Coveler AL, Herman JM, Simeone DM, et al. Localized pancreatic cancer: multidisciplinary management. Am Soc Clin Oncol Educ Book. 2016;35:e217–26.CrossRefPubMed Coveler AL, Herman JM, Simeone DM, et al. Localized pancreatic cancer: multidisciplinary management. Am Soc Clin Oncol Educ Book. 2016;35:e217–26.CrossRefPubMed
3.
go back to reference Uesaka K, Boku N, Fukutomi A, et al; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–257.CrossRefPubMed Uesaka K, Boku N, Fukutomi A, et al; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–257.CrossRefPubMed
4.
go back to reference Neoptolemos JP, Palmer DH, Ghaneh P, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.CrossRefPubMed Neoptolemos JP, Palmer DH, Ghaneh P, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.CrossRefPubMed
5.
go back to reference Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.CrossRefPubMed Sohal DP, Walsh RM, Ramanathan RK, et al. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. J Natl Cancer Inst. 2014;106:dju011.CrossRefPubMed
6.
go back to reference Ito T, Sugiura T, Okamura Y, et al. The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer. Pancreatology. 2017;17:451–456.CrossRefPubMed Ito T, Sugiura T, Okamura Y, et al. The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer. Pancreatology. 2017;17:451–456.CrossRefPubMed
7.
go back to reference Yeh R, Steinman J, Luk L, et al. Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging. 2017;42:203–217.CrossRefPubMed Yeh R, Steinman J, Luk L, et al. Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging. 2017;42:203–217.CrossRefPubMed
8.
go back to reference Okabayashi T, Shima Y, Iwata J, et al. Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion. Langenbecks Arch Surg. 2015;400:487–494.CrossRefPubMed Okabayashi T, Shima Y, Iwata J, et al. Reconsideration about the aggressive surgery for resectable pancreatic cancer: a focus on real pathological portosplenomesenteric venous invasion. Langenbecks Arch Surg. 2015;400:487–494.CrossRefPubMed
9.
go back to reference Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.CrossRefPubMed Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.CrossRefPubMed
10.
go back to reference Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–771.CrossRefPubMed Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–771.CrossRefPubMed
12.
13.
go back to reference Cespedes Feliciano EM, Kroenke CH, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol. 2017;3(12):e172319.CrossRefPubMedCentral Cespedes Feliciano EM, Kroenke CH, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol. 2017;3(12):e172319.CrossRefPubMedCentral
14.
go back to reference Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19–9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681–689.CrossRefPubMed Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19–9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681–689.CrossRefPubMed
15.
go back to reference Stevens L, Pathak S, Nunes QM, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford). 2015;17:285–291.CrossRefPubMed Stevens L, Pathak S, Nunes QM, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford). 2015;17:285–291.CrossRefPubMed
16.
go back to reference Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028–1061.CrossRefPubMed Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028–1061.CrossRefPubMed
17.
go back to reference Bockhorn M, Uzunoglu FG, Adham M, et al; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–988.CrossRefPubMed Bockhorn M, Uzunoglu FG, Adham M, et al; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–988.CrossRefPubMed
18.
go back to reference Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.CrossRefPubMed Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.CrossRefPubMed
19.
go back to reference Otani Y, Okabayashi T, Shima Y, et al. Safety and efficacy of the surgical management of hemodialysis patients with gastric cancer. Acta Med Okayama. 2017;71:333–339.PubMed Otani Y, Okabayashi T, Shima Y, et al. Safety and efficacy of the surgical management of hemodialysis patients with gastric cancer. Acta Med Okayama. 2017;71:333–339.PubMed
20.
go back to reference Sierzega M, Lenart M, Rutkowska M, et al. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol. 2017;24:808–815.CrossRefPubMed Sierzega M, Lenart M, Rutkowska M, et al. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol. 2017;24:808–815.CrossRefPubMed
21.
go back to reference Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol. 2017;24:561–568.CrossRefPubMed Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol. 2017;24:561–568.CrossRefPubMed
22.
go back to reference Hamaguchi Y, Kaido T, Okumura S, et al. Impact of skeletal muscle mass index, intramuscular adipose tissue content, and visceral to subcutaneous adipose tissue area ratio on early mortality of living donor liver transplantation. Transplantation. 2017;101:565–574.CrossRefPubMed Hamaguchi Y, Kaido T, Okumura S, et al. Impact of skeletal muscle mass index, intramuscular adipose tissue content, and visceral to subcutaneous adipose tissue area ratio on early mortality of living donor liver transplantation. Transplantation. 2017;101:565–574.CrossRefPubMed
23.
go back to reference Humphris JL, Chang DK, Johns AL, et al; NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–1722.CrossRefPubMedPubMedCentral Humphris JL, Chang DK, Johns AL, et al; NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–1722.CrossRefPubMedPubMedCentral
Metadata
Title
A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer
Authors
Takehiro Okabayashi, MD
Yasuo Shima, MD
Tatsuaki Sumiyoshi, MD
Kenta Sui, MD
Jun Iwata, MD
Sojiro Morita, MD
Yasuhiro Shimada, MD
Tatsuo Iiyama, MD
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6485-7

Other articles of this Issue 7/2018

Annals of Surgical Oncology 7/2018 Go to the issue